Humacyte (HUMA) Total Current Liabilities (2020 - 2026)

Humacyte (HUMA) has 7 years of Total Current Liabilities data on file, last reported at $16.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $16.2 million, down 19.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.2 million (down 19.18% YoY), and the FY2025 annual result was $18.4 million, down 7.93% from the prior year.
• Total Current Liabilities declined to $16.2 million in Q1 2026 per HUMA's latest filing, from $18.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $25.6 million in Q3 2025 and troughed at $10.8 million in Q1 2022.
• A 5-year average of $17.8 million and a median of $18.4 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities soared 7834.57% in 2022, then tumbled 40.31% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $19.6 million in 2022, then slipped by 5.81% to $18.4 million in 2023, then climbed by 8.19% to $20.0 million in 2024, then fell by 7.93% to $18.4 million in 2025, then retreated by 11.89% to $16.2 million in 2026.
• Business Quant data shows HUMA's Total Current Liabilities at $16.2 million in Q1 2026, $18.4 million in Q4 2025, and $25.6 million in Q3 2025.